SCHEMBL347473

SCHEMBL347473

[NH]C(=N)Oc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 2/20 0.41
ATM Q13315 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALOX15 P16050 2/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CA5A P35218 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
CA4 P22748 1/20 0.39
NR1H2 P55055 1/20 0.39
BAX Q07812 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
NSD2 O96028 1/20 0.38
ALDH1A1 P00352 1/20 0.37
RECQL P46063 1/20 0.37
SRC P12931 1/20 0.37
F2 P00734 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9748734 0.80 LTA4H (0.45) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL2665439 0.80 LTA4H (0.45) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL9748729 0.80 LTA4H (0.45) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL55400 0.78 TDP1 (0.52) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL3688619 0.78 LTA4H (0.43) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL13665356 0.76 CA4 (0.43) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL7346936 0.76 LTA4H (0.41) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL2213828 0.76 F2 (0.46) LTA4HTSHRTDP1ATML3MBTL1
SCHEMBL21811709 0.74 F2 (0.44) LTA4HTSHRTDP1ATML3MBTL1
Hydrochloric Acid SCHEMBL9505480 0.74 BLM (0.48) LTA4HTSHRTDP1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415756-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-02-08 EP claimed
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-01-19 US claimed
EP-2415756-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, BACE2, APP LTA4H 1996/4885TSHR 837/4885TDP1 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.